Sign in
TerminatedNo phase

Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Bethesda, United StatesSee the site
Trial code
Status
Terminated
People taking part
3 people enrolled
Started
20 Mar 2024
Ended
10 Sept 2024
Type of study
Observational
Record updated
10 July 2025
Why it stopped
Slow accrual.

Who can take part

Age
35 years to 120 years
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who cannot take part

  • Prior prostate biopsy
  • Prior radiotherapy or surgery for prostate cancer
  • Prior or ongoing hormonal therapy or chemotherapy (e.g., docetaxel) for prostate cancer
  • Participants unwilling or unable to undergo MRI, including participants with contraindications to MRI
  • Participants unwilling or unable to undergo biopsy, including participants with contraindications to biopsy

Other criteria

  • INCLUSION CRITERIA:
  • Age >35 years
  • Men self-identified as being of African Ancestry
  • Elevated serum prostate specific antigen of >=3ng/ml and/or positive digital rectal examination and/or strong family history of prostate cancer (at least 1 first or second degree male relative)
  • ECOG performance status <=2
  • Ability of participant to understand and the willingness to sign a written informed consent document
  • Must be co-enrolled in protocols 16-C-0010 and/or 18-C-0017

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United States

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Prostate cancer (PCa) is one of the most common cancers in American men; it is a leading cause of death. Men of African ancestry have a higher rate of prostate cancer, and a higher likelihood of death, compared to men of European ancestry. The reasons for these higher rates are not known; they may include genetic and environmental factors. Better screening methods are needed.

Objective:

To test an imaging technology called multiparametric magnetic resonance imaging (mpMRI) for detecting prostate cancer in men of African ancestry.

Eligibility:

Men of African ancestry aged 35 years or older with prostate cancer and/or a strong family history of prostate cancer.

Design:

Participants will be screened. They will have a physical exam with blood and urine tests.

Participants will have an mpMRI. They will lie on a narrow bed that slides into a large cylinder. They will lie still for about 45 minutes. They will hear loud noises during the scan; they may wear earplugs or headphones to muffle the sound. Some participants may have a dye injected into a vein.

If the scan indicates participants risk of prostate cancer is medium or high, they will have a biopsy: The area will be numbed, and samples of tissue will be removed from the prostate. The biopsy will be done within 6 months.

If the scan indicates participants risk of prostate cancer is low, they will not have a biopsy.

All participants will be followed for 5 years. They and/or their local doctors will be contacted once a year for follow-up. Additional mpMRIs may be recommended.

The group in the trial

  • Cohort 1

    Participants of African Ancestry with elevated serum prostate specific antigen of (Bullet)3ng/ml or positive digital rectal examination or strong family history.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Record updated
10 July 2025